Although IL-1β has the potential to improve adoptive cell therapy (156), IL-1β in conjunction with macrophage-derived nitric oxide and IL-6 plays a central role in cytokine release syndrome (CRS) (157, 158), a serious complication of CAR T cell therapy. Here, IL1B is linked to congenital rubella syndrome.